Ixekizumab for the treatment of the patients with moderate to severe plaque psoriasis: Clinical data from a real-world experience [0.03%]
伊克珠单抗治疗中重度斑块状银屑病患者的真实世界临床数据
Melis Gönülal,İlknur Kıvanç Altunay,Sinan Doğan et al.
Melis Gönülal et al.
Real-life data about any particular treatment is very helpful for clinicians, particularly when managing a chronic disease such as psoriasis. In our study, we aimed to reflect our clinical experience during 48 weeks with an IL-17 antagonist...
Multicenter Study
Dermatologic therapy. 2022 Dec;35(12):e15955. DOI:10.1111/dth.15955 2022
Long lasting response to anti-tumor necrosis factor α agents in psoriasis: A real life experience [0.03%]
肿瘤坏死因子α抑制剂治疗银屑病长期疗效的临床观察
Maria Letizia Musumeci,Andrea Calogero Trecarichi,Giuliana Caruso et al.
Maria Letizia Musumeci et al.
Psoriasis is a chronic, immune-mediated inflammatory disease for which no definitive cure exists and patients difficult to treat with moderate to severe psoriasis often require life-long therapy. In general, the use of any biologic agent as...
Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long-term efficacy and patient-reported outcomes [0.03%]
巴利西替尼2mg治疗北美地区特应性皮炎的长期疗效和患者报告结果
Eric Simpson,April Armstrong,Mark Boguniewicz et al.
Eric Simpson et al.
To address the need for long-term efficacy and patient-reported outcomes (PROs) data for patients with atopic dermatitis (AD) treated with baricitinib 2 mg, a study was conducted to evaluate the efficacy of baricitinib 2 mg in adult patient...
Multicenter Study
Dermatologic therapy. 2022 Dec;35(12):e15954. DOI:10.1111/dth.15954 2022
A case of atopic dermatitis-associated dupilumab-resistant alopecia totalis successfully treated with baricitinib [0.03%]
一例对度普利尤单抗抵抗的特应性皮炎相关斑片状全秃成功应用巴瑞克替尼治疗的病例报告
Takashi Seo,Kentaro Izumi,Takuya Kawamura et al.
Takashi Seo et al.
Case Reports
Dermatologic therapy. 2022 Dec;35(12):e15953. DOI:10.1111/dth.15953 2022
Sub-erythrodermic psoriasis successfully treated with bimekizumab: A case report [0.03%]
贝墨珠单抗治疗中至重度银屑病1例报告
Mario Valenti,Luigi Gargiulo,Luciano Ibba et al.
Mario Valenti et al.
Case Reports
Dermatologic therapy. 2022 Dec;35(12):e15952. DOI:10.1111/dth.15952 2022
Sharpen your sight: Trombiculosis under the dermatoscope with LC-OCT new insights [0.03%]
提高警惕——皮肤镜联合光学 coherence tomography诊断 trombiculosis的新见解
Simone Cappilli,Enrico Bocchino,Luigi Cornacchia et al.
Simone Cappilli et al.
Variation of body regional responses to Ustekinumab and Secukinumab in psoriasis patients: A real-world retrospective study and literature review [0.03%]
生物制剂乌司奴单抗和塞库奴单抗治疗银屑病患者的不同部位应答变异：真实世界回顾性研究与文献分析
Pai-Shan Cheng,Ping-Chen Hou,Chao-Chun Yang et al.
Pai-Shan Cheng et al.
Psoriasis in different body regions displays varying therapeutic responses to biologics, whereas currently relevant studies remain scarce. We retrospectively reviewed the treatment responses of patients with moderate-to-severe psoriasis, wh...
Influence of serum vitamin D level in the response of actinic keratosis to ingenol mebutate [0.03%]
血清维生素D水平对肉毒素甲苯达松治疗角化病的影响研究
Ricardo Moreno-Alonso de Celada,Tamara Gracia-Cazaña,Laura Najera-Botello et al.
Ricardo Moreno-Alonso de Celada et al.
Vitamin D (VD) serum levels, and keratinocytic basal expression of vitamin D receptor (VDR) before treatment of actinic keratoses (AK) have been previously reported as possible biomarkers of the response of AK to treatments. We intended to ...
Intravenous immunoglobulin therapy in children with severe atopic dermatitis [0.03%]
儿童重度特应性皮炎的静脉用免疫球蛋白治疗
Zhen Zhang,Jiawen Chen,Yijun Yang et al.
Zhen Zhang et al.
Children with severe atopic dermatitis (AD) can benefit from intravenous immunoglobulin (IVIG) therapy. This study aimed to identify the efficacy and safety of IVIG therapy in children with severe AD. Twenty pediatric AD patients were enrol...
Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid [0.03%]
omalizumab作为减少糖皮质激素使用的一种手段在天疱疮治疗中的应用
Camilla Vassallo,Anita Somenzi,Mara De Amici et al.
Camilla Vassallo et al.
Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease, characterized by the development of autoantibodies against hemidesmosomal components BP180 and BP230. The mainstay of therapy is topical and systemic corticoster...